Literature DB >> 27557820

PHB in Cardiovascular and Other Diseases: Present Knowledge and Implications.

Debabrata Chowdhury1, Dinesh Kumar1, Pranjal Sarma1, Anjana Devi Tangutur1, Manika Pal Bhadra1.   

Abstract

BACKGROUND: Prohibitin (PHB) is overtly conserved evolutionarily and ubiquitously expressed protein with pleiotropic functions in diverse cellular compartments. However, regulation and function of these proteins in different cells, tissues and in various diseases is different as evidenced by expression of these proteins which is found to be reduced in heart diseases, kidney diseases, lung disease, Crohn's disease and ulcerative colitis but this protein is highly expressed in diverse cancers. The mechanism by which this protein acts at the molecular level in different subcellular localizations or in different cells or tissues in different conditions (diseases or normal) has remained poorly understood. There are several studies reported to understand and decipher PHB's role in diseases and/or cancers of ovary, lung, stomach, thyroid, liver, blood, prostrate, gastric, esophagus, glioma, breast, bladder etc. where PHB is shown to act through mechanisms by acting as oncogene, tumor suppressor, antioxidant, antiapoptotic, in angiogenesis, autophagy etc.
OBJECTIVE: This review specifically gives attention to the functional role and regulatory mechanism of PHB proteins in cardiovascular health and diseases and its associated implications. Various molecular pathways involved in PHB function and its regulation are analyzed.
CONCLUSION: PHB is rapidly emerging as a critical target molecule for cardiovascular signaling. Progress in delineating CVD and mechanisms of PHB in diverse molecular pathways is essential for determining when and how PHB targeted therapy might be feasible. In this regard, new therapies targeting PHB may best be applied in the future together with molecular profiling of CVD for clinical stratification of disease diagnosis and prognosis. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  CVD; Prohibitin; mitochondria; other diseases; oxidative stress; post-transcriptional and post-translational regulation

Mesh:

Substances:

Year:  2017        PMID: 27557820     DOI: 10.2174/1389450117666160824161225

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  4 in total

1.  The Synthetic Small Molecule FL3 Combats Intestinal Tumorigenesis via Axin1-Mediated Inhibition of Wnt/β-Catenin Signaling.

Authors:  Dakota N Jackson; Kibrom M Alula; Yaritza Delgado-Deida; Redouane Tabti; Kevin Turner; Xuan Wang; K Venuprasad; Rhonda F Souza; Laurent Désaubry; Arianne L Theiss
Journal:  Cancer Res       Date:  2020-07-14       Impact factor: 12.701

Review 2.  Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases.

Authors:  Dong Wang; Redouane Tabti; Sabria Elderwish; Hussein Abou-Hamdan; Amel Djehal; Peng Yu; Hajime Yurugi; Krishnaraj Rajalingam; Canan G Nebigil; Laurent Désaubry
Journal:  Cell Mol Life Sci       Date:  2020-02-15       Impact factor: 9.261

3.  The prohibitin-binding compound fluorizoline affects multiple components of the translational machinery and inhibits protein synthesis.

Authors:  Xin Jin; Jianling Xie; Michael Zabolocki; Xuemin Wang; Tao Jiang; Dong Wang; Laurent Désaubry; Cedric Bardy; Christopher G Proud
Journal:  J Biol Chem       Date:  2020-05-19       Impact factor: 5.157

4.  Mitochondrial dysfunction during loss of prohibitin 1 triggers Paneth cell defects and ileitis.

Authors:  Dakota N Jackson; Marina Panopoulos; William L Neumann; Kevin Turner; Brandi L Cantarel; LuAnn Thompson-Snipes; Themistocles Dassopoulos; Linda A Feagins; Rhonda F Souza; Jason C Mills; Richard S Blumberg; K Venuprasad; Winston E Thompson; Arianne L Theiss
Journal:  Gut       Date:  2020-02-28       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.